
BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Melissa A. Herman

eRA COMMONS USER NAME (credential, e.g., agency login): melissaher

POSITION TITLE: Assistant Professor

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Boston University, Boston MA	B.S.	06/2001	Human physiology
Georgetown University, Washington DC	Ph.D.	06/2010	Neuroscience
The Scripps Research Institute, La Jolla CA	Post-doc	08/2015	Neuropharmacology

A. Personal Statement

I am an Assistant Professor in the Pharmacology Department and a member of the Bowles Center for Alcohol Studies at the University of North Carolina at Chapel Hill. I have a broad background in neurophysiology and pharmacology and have been trained as a multidisciplinary scientist. My research interests involve the structure of inhibitory neuronal networks and how these networks change to produce adverse behavioral outcomes. My main interest is how the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) regulates neuronal networks via both synaptic and extrasynaptic forms of inhibition and how alterations in inhibitory networks contribute to clinical conditions such as alcohol use disorder, nicotine dependence, drug abuse, anxiety, depression, and/or stress. I am also an active member of the Pharmacology training program. I have received training in mentoring and laboratory management from my junior faculty mentoring committee as well as informal advice and guidance from colleagues and collaborators. I teach lectures in the UNC graduate level curriculum, act as a faculty mentor in the graduate student First Year Group course, serve on graduate thesis committees, and mentor predoctoral students in my laboratory. I prioritize mentoring and work to maintain a diverse and inclusive mentoring environment. I meet with trainees on a regular basis, including weekly individual meetings and weekly meetings of the entire laboratory. As a mentor, I focus on my trainees' scientific and professional development, and employ individual development plans (IDPs) to track goals, expectations, and progress of each of my trainees. I provide the necessary resources and support for them to conduct innovative research which they then present at local meetings, such as student seminars, and at relevant annual meetings and scientific conferences. I am currently mentoring 1 graduate student, 2 postdoctoral trainees, and 3 undergraduates. Mentoring students at all levels (undergraduate to postdoctoral fellows) has enriched my independent research program through participating in community outreach and scientific communication, lecturing to students, attending seminars and student talks, and serving on student thesis committees.

Positions

- 1997-2001 **Boston University** (Boston, MA) – Sargent College of Health and Rehabilitation Studies
Undergraduate Student
- 2001-2005 **The Salk Institute for Biological Studies** (La Jolla, CA) – Department of Peptide Biology
Research Assistant
Advisor: Dr. Catherine Rivier
- 2005-2010 **Georgetown University Medical School** (Washington DC) – Department of Pharmacology
Graduate Student
Advisor: Richard Gillis
- 2010-2015 **The Scripps Research Institute** (La Jolla, USA) - Committee on the Neurobiology of Addictive Disorders

Research Associate (postdoc)
Advisor: Dr. Marisa Roberto

2016-present **The University of North Carolina** (Chapel Hill, NC) – Department of Pharmacology, Bowles Center for Alcohol Studies
Assistant Professor

Professional Memberships and Activities

2005-present Society for Neuroscience
2011-present Research Society on Alcoholism
2013-2014 FRONTIERS SPECIAL TOPICS JOURNAL EDITOR
Co-Editor of “Neurophysiological mechanisms of addictive disorders”
Special Topic for *Frontiers in Integrative Neuroscience*

Honors

1998, 2001 Boston University Dean’s List
2006-2009 Travel Award Georgetown University Medical Center Graduate Student Organization
2010 Ph.D. Distinction Award, Georgetown University Medical Center
2011, 2013 Travel Award, NIAAA Special Meeting "Alcoholism and Stress: a Framework for Future Treatment Strategies" Volterra, Italy
2011-2014 Individual Post-doctoral fellowship from NIAAA F32 AA020430
2013 Poster Award NIAAA Special Meeting "Alcoholism and Stress: a Framework for Future Treatment Strategies" Volterra, Italy
2017 Young Investigator Award, NIAAA Special Meeting "Alcoholism and Stress: a Framework for future treatment strategies" Volterra, Italy
2018 UNC Junior Faculty Development Award
2018 American College of Neuropsychopharmacology Travel Award

C. Contribution to Science

Over my career, I have published over 25 scientific articles in the field of neuropharmacology. These accomplishments are broken into several general themes that are relevant to the proposed studies.

1. Brainstem inhibitory networks regulating gastric function. The role of the autonomic nervous system in the central control of gastric function is well known, however, the specific signaling and circuitry mediating this control remain poorly understood. My early work focused on the role of inhibitory signaling in the brainstem nucleus the Nucleus Tractus Solitarius (NTS) and the role of inhibition in the central control of gastric function. My work revealed an important role for inhibitory signaling in the NTS in the control of basal gastric function. I also reported on a novel form of inhibition in the NTS, tonic or extrasynaptic inhibition, and showed how tonic inhibition acted as a critical regulator of overall network activity in the NTS. In addition, I showed how stimulation of the mu-opioid receptor in the NTS altered inhibitory function by dampening tonic inhibition resulting in diminished gastric tone. Collectively this work demonstrates the importance of inhibitory control in maintaining physiological gastric function and provides a central mechanism by which opioid therapeutics can produce adverse gastric side effects.
 - a) **Herman MA**, Cruz MT, Sahibzada N, Verbalis JG, Gillis RA. GABA signaling in the Nucleus Tractus Solitarius sets the level of activity in Dorsal Motor Nucleus of the Vagus cholinergic neurons in the vago-vagal circuit. *Am J Physiol Gastrointest Liver Physiol.* 2009 Jan;296(1):G101-11.
 - b) **Herman MA**, Alayan A, Sahibzada N, Bayer B, Verbalis JG, Dretchen K, Gillis RA. Mu-opioid receptor stimulation in the medial subnucleus of the tractus solitarius (mNTS) inhibits gastric tone and motility by reducing local GABA activity. *Am J Physiol Gastrointest Liver Physiol.* 2010 Aug;299(2):G494-506.

c) Herman MA, Gillis RA, Vicini S, Dretchen K, Sahibzada N. Tonic GABAA receptor conductance in medial subnucleus of the tractus solitarius (mNTS) neurons is inhibited by activation of μ -opioid receptors. *J Neurophysiol.* 2012 Feb;107(3):1022-31.

d) Valentino RJ, Guyenet P, Hou XH, **Herman M**. Central Network Dynamics Regulating Visceral and Humoral Functions. *J Neurosci.* 2017 Nov 8;37(45):10848-10854

2. Inhibitory microcircuitry and the effects of ethanol in the central amygdala. The central nucleus of the amygdala (CeA) is a key brain region in the negative reinforcing properties of ethanol and has been implicated in both the development of alcohol dependence as well as the susceptibility to relapse in dependent individuals. Inhibitory signaling in the CeA has been shown to play a major role in both the effects of acute ethanol as well as the neuroadaptations that occur in response to chronic ethanol exposure. Until recently, the majority of the work done has been focused on phasic or synaptic inhibition and has treated the CeA as a homogenous nucleus, with little investigation into cell type-specific effects. In my work I utilized a transgenic reporter mouse expressing green fluorescent protein (GFP) under the control of the CRF receptor 1 promoter to identify CRF1-expressing (GFP+) neurons in the CeA. Using these mice as well as a rat model, I uncovered cell type-specific expression of tonic inhibitory signaling in CeA neurons with differential sensitivity to the effects of acute ethanol. I also identified a local inhibitory microcircuit within the CeA which provides the local synaptic mechanism for the divergent effects of acute ethanol on the firing of distinct CeA neurons. The types of tonic inhibition in the CeA are selectively altered by exposure to chronic intermittent ethanol, with significant consequences for overall ceA network function. In addition, work in mice containing a genetic deletion of the interleukin receptor 1 receptor antagonist revealed that tonic inhibition was selectively altered in CeA neurons in a manner similar to what was observed following chronic ethanol exposure. This work highlights the significance of tonic inhibition in the physiological functioning of the CeA and adds tonic signaling to the neuroadaptations that occur with chronic alcohol exposure and further suggests that alterations in tonic signaling is implicated in other pathophysiological conditions like inflammation and/or stress.

a) Herman MA, Contet C, Justice NJ, Vale W & Roberto M. Novel subunit-specific tonic GABA currents and differential effects of ethanol in the central amygdala of CRF receptor-1 reporter mice. *J Neurosci* 2013, 33(8):3284-98. PMC3711798.

b) Herman MA and Roberto M. Cell type-specific tonic GABA signaling in the rat central amygdala is selectively altered by acute and chronic ethanol. *Addiction biology.* 2016; 21(1):72-86.

c) Herman MA, Contet C, Roberto M. A functional switch in tonic GABA currents alters the output of central amygdala CRF receptor-1 neurons following chronic ethanol exposure. *J Neurosci* 2016; 36(42):10729-10741.

d) Agoglia A., Herman MA. The Center of the Emotional Universe: alcohol, stress, and CRF1 amygdala circuitry. 2018. Alcohol. In press.

3. The role of inhibitory control of the ventral tegmental area in reward processing. The ventral tegmental area (VTA) is a major component of the mesolimbic dopamine reward pathway. Changes in the activity of dopamine neurons in the VTA is associated with increased (or decreased) dopamine release in target brain regions like the nucleus accumbens and this signaling is thought to provide one aspect of the cellular basis for reward signaling. Accordingly, certain drugs of abuse are known to selectively engage dopamine neurons in the VTA and this signaling is thought to contribute to the development of addiction. Despite the importance of changes in the excitability of VTA dopamine neurons in normal reward processing as well dysregulation of this signaling in pathological conditions such as addiction and psychiatric disorders like depression, the cellular mechanisms controlling the firing of dopamine neurons are poorly understood. My work has examined inhibitory and excitatory regulation of dopamine neurons in the VTA. Specifically, I have shown that activation of the dopamine D2 receptor and the CRF receptor increases excitatory signaling at VTA dopamine neurons. I have also shown that inhibitory control of VTA

dopamine neurons is compromised by chronic exposure to nicotine in a mechanism involving the CRF system and that the excitatory actions of ethanol in VTA dopamine neurons is mediated at least in part by the G protein-gated inwardly-rectifying potassium (GIRK) 3 subunit channel.

a) Grieder TE, **Herman M**, Contet C, Tan LA, Vargas-Perez H, Cohen A, Chwalek M, Maal-Bared G, Freiling J, Schlosburg JE, Clarke L, Crawford E, Koebel P, Canonigo V, Sanna P, Tapper A, Roberto M, Kieffer BL, Sawchecko PE, Koob GF, van der Kooy D & George O. CRF neurons in the ventral tegmental area control the aversive effects of nicotine withdrawal and promote escalation of nicotine intake. *Nature Neurosci* 2014, 17(12):1751-8. PMC4241147.

b) Buczynski MW¹, **Herman MA**¹, Hsu KL¹, Natividad LA, Irimia C, Polis IY, Pugh H, Chang JW, Niphakis MJ, Cravatt BF, Roberto M, Parsons LH. Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure. *Proceedings of the National Academy of Sciences of the United States of America*. 2016; 113(4):1086-91.

c) **Herman MA**, Munoz MB, Le D, Kreifeldt M, Stouffer DG, Parsons LH, Roberto M, Roberts AJ, Wickman K, Slesinger PA and Contet C. GIRK3 gates activation of the mesolimbic dopaminergic pathway by ethanol. *Proc Natl Acad Sci*. 2015 Jun 2;112(22):7091-6.

Complete List of Published Work in MyBibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/melissa.herman.1/bibliography/43552900/public/?sort=date&direction=descending>